ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 284.00 thousand shares for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 26.00K shares, a 46.94% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 6.00K shares, a 97.73% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 252.00K shares, a 116029.03% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 65.00K shares.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 379.00K shares.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2014 was 465.00 shares, a 83.76% decline from fiscal 2013.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2013 was 2.86K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 26.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | 32.00K shares derived: sum of 2 quarters · filed 2026-08-12 | 284.00K shares 10-Q · filed 2026-08-12 | 349.00K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 6.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | 258.00K shares 10-Q · filed 2026-05-13 | 323.00K shares derived: sum of 3 quarters · filed 2026-05-13 | 372.00K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 252.00K shares 10-Q · filed 2026-02-11 | 317.00K shares derived: sum of 2 quarters · filed 2026-02-11 | 366.00K shares derived: sum of 3 quarters · filed 2026-02-11 | 630.78K shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-09-30 | 65.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | 114.00K shares derived: sum of 2 quarters · filed 2025-11-19 | 378.78K shares derived: sum of 3 quarters · filed 2025-11-19 | 379.00K shares 10-K · filed 2025-11-19 |
| 2025-06-30 | 49.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13 | 313.78K shares derived: sum of 2 quarters · filed 2025-08-13 | 314.00K shares 10-Q · filed 2025-08-13 | |
| 2025-03-31 | 264.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | 265.00K shares 10-Q · filed 2025-05-14 | ||
| 2024-12-31 | 217.00 shares 10-Q · filed 2025-02-12 | |||
| 2015-06-30 | 30.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | 35.76K shares derived: sum of 2 quarters · filed 2015-08-10 | 39.48K shares 10-Q · filed 2015-08-10 | 39.48K shares derived: sum of 4 quarters · filed 2015-08-10 |
| 2015-03-31 | 4.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | 8.63K shares 10-Q · filed 2015-05-08 | 8.63K shares derived: sum of 3 quarters · filed 2015-05-08 | 8.63K shares derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | 3.73K shares 10-Q · filed 2015-02-06 | 3.73K shares derived: sum of 2 quarters · filed 2015-02-06 | 3.73K shares derived: sum of 3 quarters · filed 2015-02-06 | 3.73K shares derived: sum of 4 quarters · filed 2015-02-06 |
| 2014-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | 0.00 shares derived: sum of 2 quarters · filed 2014-12-11 | 1.00 shares derived: sum of 3 quarters · filed 2014-12-11 | 465.00 shares 10-K · filed 2014-12-11 |
| 2014-06-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12 | 1.00 shares derived: sum of 2 quarters · filed 2014-08-12 | 465.00 shares 10-Q · filed 2014-08-12 | 465.00 shares derived: sum of 4 quarters · filed 2014-08-12 |
| 2014-03-31 | 1.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | 465.00 shares 10-Q · filed 2014-05-12 | 465.00 shares derived: sum of 3 quarters · filed 2014-05-12 | 465.00 shares derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-12-31 | 464.00 shares 10-Q · filed 2014-02-13 | 464.00 shares derived: sum of 2 quarters · filed 2014-02-13 | 464.00 shares derived: sum of 3 quarters · filed 2014-02-13 | |
| 2013-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18 | 0.00 shares derived: sum of 2 quarters · filed 2013-12-18 | 2.86K shares 10-K · filed 2013-12-18 | |
| 2013-06-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | 2.86K shares 10-Q · filed 2013-08-12 | ||
| 2013-03-31 | 2.86K shares 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |